Is there a role for the nuclear receptor PPARγ in neuropsychiatric diseases?

International Journal of Neuropsychopharmacology

Volumn 13, Issue 10, 2010, Pages 1411-1429

  García Bueno, Borja ^a   Pérez Nievas, Beatriz G ^a   Leza, Juan C ^a  

^a Instituto de Investigación Hospital 12 de Octubre ^*  (Spain)

Author keywords

Depression; neuroinflammation; PPAR , schizophrenia.; prostanoids

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ARACHIDONIC ACID; BIOLOGICAL MARKER; CANNABINOID DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROSTANOID; ROSIGLITAZONE; CELL RECEPTOR;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARACHIDONIC ACID METABOLISM; DEPRESSION; DRUG TARGETING; HUMAN; IMMUNOREGULATION; INFLAMMATION; MENTAL DISEASE; NEUROPATHOLOGY; NEUROPSYCHIATRY; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRESS; ARTICLE; METABOLISM; NERVE CELL; SCHIZOPHRENIA;

HUMANS; INFLAMMATION; MENTAL DISORDERS; NEURONS; PPAR GAMMA; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SCHIZOPHRENIA;

EID: 79952713816     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145710000970     Document Type: Review

References (175)

1. Akhondzadeh S, Jafari S, Raisi F, Nasehi AA, et al. (2009). Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depression and Anxiety 26, 607-611.
2. Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, et al. (2007). Celecoxib as adjunctive therapy in schizophrenia : a double-blind, randomized and placebo-controlled trial. Schizophrenia Research 90, 179-185. (Pubitemid 46177578)
3. Allan SM, Rothwell NJ (2003). Inflammation in central nervous system injury. Philosophical Transactions of the Royal Society of London, Series B: Biological Sciences 358, 1669-1677. (Pubitemid 37298635)
4. Altamura AC, Boin F, Maes M (1999). HPA axis and cytokines dysregulation in schizophrenia: potential implications for the antipsychotic treatment. European Neuropsychopharmacology 10, 1-4.
5. APA (2000). Diagnostic and Statistical Manual of Mental Disorders - Text Revision, 4th edn (DSM-IV-TR). Washington, DC: American Psychiatric Association.
6. Angelucci F, Mathé AA, Aloe L (2000). Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered after haloperidol and risperidone administration. Journal of Neuroscience Research 60, 783-794. (Pubitemid 30399550)
7. Bagary MS, Symms MR, Barker GJ, Mutsatsa SH, et al. (2003). Gray and white matter brain abnormalities in first-episode schizophrenia inferred from magnetization transfer imaging. Archives of General Psychiatry 60, 779-788. (Pubitemid 36960909)
8. Balu DT, Lucki I (2009). Adult hippocampal neurogenesis: regulation, functional implications, and contribution to disease pathology. Neuroscience and Biobehavioural Reviews 33, 232-252.
9. Barbosa NR, Junqueira RM, Vallada HP, Gattaz WF (2007). Association between BanI genotype and increased phospholipase A2 activity in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience 257, 340-343. (Pubitemid 47476721)
10. Basselin M, Chang L, Bell JM, Rapoport SI (2005a). Chronic lithium chloride administration to unanesthetized rats attenuates brain dopamine D2-like receptor-initiated signaling via arachidonic acid. Neuropsychopharmacology 30, 1064-1075. (Pubitemid 40720964)
11. Basselin M, Chang L, Bell JM, Rapoport SI (2006). Chronic lithium chloride administration attenuates brain NMDA receptor-initiated signaling via arachidonic acid in unanesthetized rats. Neuropsychopharmacology 31, 1659-1674. (Pubitemid 44106697)
12. Basselin M, Chang L, Seemann R, Bell JM, et al. (2005b). Chronic lithium administration to rats selectively modifies 5-HT2A/2C receptor-mediated brain signaling via arachidonic acid. Neuropsychopharmacology 30, 461-472. (Pubitemid 40271149)
13. Bayer TA, Buslei R, Havas L, Falkai P (1999). Evidence for activation of microglia in patients with psychiatric illnesses. Neuroscience Letters 271, 126-128. (Pubitemid 29400683)
14. Bierhaus A, Wolf J, Andrassy M, Rohleder N, et al. (2003). A mechanism converting psychosocial stress into mononuclear cell activation. Proceedings of the National Academy of Sciences USA 100, 1920-1925. (Pubitemid 36254549)
15. Black PH (2006). The inflammatory consequences of psychologic stress : relationship to insulin resistance, obesity, atherosclerosis and diabetes mellitus, type II. Medical Hypotheses 67, 879-891. (Pubitemid 44062125)
16. Bosetti F, Rintala J, Seemann R, Rosenberger TA, et al. (2002). Chronic lithium downregulates cyclooxygenase-2 activity and prostaglandin E(2) concentration in rat brain. Molecular Psychiatry 7, 845-850.
17. Brodbeck J, Balestra ME, Saunders AM, et al. (2008). Rosiglitazone increases dendritic spine density and rescues spine loss caused by apolipoprotein E4 in primary cortical neurons. Proceedings of the National Academy of Sciences USA 105, 1343-1346. (Pubitemid 351397055)
18. Buchsbaum MS, Hazlett EA (1998). Positron emission tomography studies of abnormal glucose metabolism in schizophrenia. Schizophrenia Bulletin 24, 343-364. (Pubitemid 28378221)
19. Buckley PF, Mahadik S, Pillai A, Terry Jr. A (2007). Neurotrophins and schizophrenia. Schizophrenia Research 94, 1-11. (Pubitemid 47033973)
20. Burstein SH, Karst M, Schneider U, Zurier RB (2004). Ajulemic acid : a novel cannabinoid produces analgesia without a 'high'. Life Sciences 75, 1513-1522. (Pubitemid 38887278)
21. Cassano P, Hidalgo A, Burgos V, Adris S, et al. (2006). Hippocampal upregulation of the cyclooxygenase-2 gene following neonatal clomipramine treatment (a model of depression). Pharmacogenomics Journal 6, 381-387. (Pubitemid 44811533)
22. Chowdari KV, Brandstaetter B, Semwal P, Bhatia T, et al. (2001). Association studies of cytosolic phospholipase A2 polymorphisms and schizophrenia among two independent family-based samples. Psychiatric Genetics 11, 207-212. (Pubitemid 34102296)
23. Dantzer R, O'Connor JC, Freund GG, Johnson RW, et al. (2008). From inflammation to sickness and depression: when the immune system subjugates the brain. Nature Review Neuroscience 9, 46-56. (Pubitemid 350295688)
24. Das I, Khan NS (1998). Increased arachidonic acid induced platelet chemiluminescence indicates cyclooxygenase overactivity in schizophrenic subjects. Prostaglandins, Leukotrienes and Essential Fatty Acids 58, 165-168. (Pubitemid 28175103)
25. De Kloet ER, Joëls M, Holsboer F (2005). Stress and the brain : from adaptation to disease. Nature Review Neuroscience 6, 463-475.
26. De Rosa MJ, Dionisio L, Agriello E, Bouzat C, et al. (2009). Alpha 7 nicotinic acetylcholine receptor modulates lymphocyte activation. Life Sciences 85, 444-449.
27. Dikeos DG, Papadimitriou GN, Souery D, Del-Favero J, et al. (2006). Lack of genetic association between the phospholipase A2 gene and bipolar mood disorder in a European multicentre case-control study. Psychiatric Genetics 16, 169-171. (Pubitemid 44491784)
28. Donohoe G, Walters J, Morris DW, Quinn EM, et al. (2009). Influence of NOS1 on verbal intelligence and working memory in both patients with schizophrenia and healthy control subjects. Archives of General Psychiatry 66, 1045-1054.
29. Doorduin J, de Vries EF, Willemsen AT, de Groot JC, et al. (2009). Neuroinflammation in schizophrenia-related psychosis: a PET study. Journal of Nuclear Medicine 50, 1801-1807.
30. Drevets WC (1998). Functional neuroimaging studies of depression: the anatomy of melancholia. Annual Review of Medicine 49, 341-361. (Pubitemid 28197459)
31. Dwivedi Y, Mondal AC, Rizavi HS, Shukla PK, et al. (2005). Single and repeated stress-induced modulation of phospholipase C catalytic activity and expression : role in LH behavior. Neuropsychopharmacology 30, 473-483. (Pubitemid 40271150)
32. Eisch AJ, Cameron HA, Encinas JM, Meltzer LA, et al. (2008). Adult neurogenesis, mental health, and mental illness : hope or hype? Journal of Neuroscience, 28, 11785-11791.
33. Eissa Ahmed AA, Al-Rasheed NM, Al-Rasheed NM (2009). Antidepressant-like effects of rosiglitazone, a PPARgamma agonist, in the rat forced swim and mouse tail suspension tests. Behavioural Pharmacology. Published online : 9 September 2009. doi: 10.1097/FBP.0b013e328331b9bf.
34. Feinstein DL (2003). Therapeutic potential of peroxisome proliferator-activated receptor agonists for neurological disease. Diabetes Technology & Therapeutics 5, 67-73. (Pubitemid 36506092)
35. Fernandez-Espejo E, Viveros MP, Núñ ez L, Ellenbroek BA, et al. (2009). Role of cannabis and endocannabinoids in the genesis of schizophrenia. Psychopharmacology (Berlin) 206, 531-549.
36. Frieboes RM, Moises HW, Gattaz WF, Yang L, et al. (2001). Lack of association between schizophrenia and the phospholipase-A(2) genes cPLA2 and sPLA2. American Journal of Medical Genetics 105, 246-249. (Pubitemid 32410896)
37. Forman BM, Chen J, Evans RM (1997). Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proceedings of the National Academy of Sciences USA 94, 4312-4317. (Pubitemid 27194238)
38. Galea E, Heneka MT, Dello Russo C, Feinstein DL (2003). Intrinsic regulation of brain inflammatory responses. Cellular and Molecular Neurobiology 23, 625-635. (Pubitemid 37071489)
39. Galve-Roperh I, Aguado T, Palazuelos J, GuzmánM(2007). The endocannabinoid system and neurogenesis in health and disease. Neuroscientist 13, 109-114. (Pubitemid 46524315)
40. Garcia-Bueno B, Caso JR, Leza JC (2008). Stress as a neuroinflammatory condition in brain : damaging and protective mechanisms. Neuroscience and Biobehavioural Reviews 32, 1136-1151.
41. Garcia-Bueno B, Caso JR, Pérez-Nievas BG, Lorenzo P, et al. (2007). Effects of peroxisome proliferator-activated receptor gamma agonists on brain glucose and glutamate transporters after stress in rats. Neuropsychopharmacology 32, 1251-1260. (Pubitemid 46788855)
42. Garcia-Bueno B, Madrigal JL, Lizasoain I, Moro MA, et al. (2005a). The anti-inflammatory prostaglandin 15d-PGJ2 decreases oxidative/nitrosative mediators in brain after acute stress in rats. Psychopharmacology (Berlin) 180, 513-522. (Pubitemid 40905040)
43. Garcia-Bueno B, Madrigal JL, Lizasoain I, Moro MA, et al. (2005b). Peroxisome proliferator-activated receptor gamma activation decreases neuroinflammation in brain after stress in rats. Biological Psychiatry 57, 885-894. (Pubitemid 40488357)
44. Gaspar PA, Bustamante ML, Silva H, Aboitiz F (2009). Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia : therapeutic implications. Journal of Neurochemistry 111, 891-900.
45. Gattaz WF, Köllisch M, Thuren T, Virtanen JA, et al. (1987). Increased plasma phospholipase-A2 activity in schizophrenic patients : reduction after neuroleptic therapy. Biological Psychiatry 22, 421-426. (Pubitemid 17041622)
46. Gattaz WF, Schmitt A, Maras A (1995). Increased platelet phospholipase A2 activity in schizophrenia. Schizophrenia Research 16, 1-6.
47. Ghelardoni S, Bazinet RP, Rapoport SI, Bosetti F (2005). Topiramate does not alter expression in rat brain of enzymes of arachidonic acid metabolism. Psychopharmacology (Berlin) 180, 523-529. (Pubitemid 40905041)
48. Ghelardoni S, Tomita YA, Bell JM, Rapoport SI, et al. (2004). Chronic carbamazepine selectively downregulates cytosolic phospholipase A2 expression and cyclooxygenase activity in rat brain. Biological Psychiatry 56, 248-254. (Pubitemid 39092939)
49. Gonzalez-Scarano F, Baltuch G (1999). Microglia as mediators of inflammatory and degenerative diseases. Annual Review of Neuroscience 22, 19-240.
50. Guo JY, Li CY, Ruan YP, Sun M, et al. (2009). Chronic treatment with celecoxib reverses chronic unpredictable stress-induced depressive-like behavior via reducing cyclooxygenase-2 expression in rat brain. European Journal of Pharmacology 612, 54-60.
51. Hall AC, Brennan A, Goold RG, Cleverley K, et al. (2002). Valproate regulates GSK-3-mediated axonal remodeling and synapsin I clustering in developing neurons. Molecular & Cellular Neuroscience 20, 257-270. (Pubitemid 34762135)
52. Hanson DR, Gottesman II (2005). Theories of schizophrenia : a genetic-inflammatory-vascular synthesis. BMC Medical Genetics 11, 7.
53. Heneka MT, Landreth GE (2007). PPARs in the brain. Biochimica et Biophysica Acta 1771, 1031-1045. (Pubitemid 47208548)
54. Hernández ME, Mendieta D, Martinez-Fong D, Loria F, et al. (2008). Variations in circulating cytokine levels during 52 week course of treatment with SSRI for major depressive disorder. European Journal of Neuropsychopharmacology 18, 917-924.
55. Houseknecht KL, Cole BM, Steele PJ (2002). Peroxisome proliferator-activated receptor gamma (PPARgamma) and its ligands: a review. Domestic Animal Endocrinology 22, 1-23. (Pubitemid 34438654)
56. Ji-Rong Y, Bi-Rong D, Chang-Quan H, Zhen-Chan L, et al. (2009). Pro12Ala polymorphism in PPARgamma2 associated with depression in Chinese nonagenarians/ centenarians. Archives of Medical Research 40, 411-415.
57. Jou SH, Chiu NY, Liu CS (2009). Mitochondrial dysfunction and psychiatric disorders. Chang Gung Medical Journal 32, 370-379.
58. Junqueira R, Cordeiro Q, Meira-Lima I, Gattaz WF, et al. (2004). Allelic association analysis of phospholipase A2 genes with schizophrenia. Psychiatric Genetics 14, 157-160. (Pubitemid 39281824)
59. Kaiya H, Uematsu M, Ofuji M, Nishida A, et al. (1989). Elevated plasma prostaglandin E2 levels in schizophrenia. Journal of Neural Transmission 77, 39-46. (Pubitemid 19140271)
60. Kapadia R, Yi JH, Vemuganti R (2008). Mechanisms of anti-inflammatory and neuroprotective actions of PPARgamma agonists. Frontiers in Bioscience 13, 1813-1826. (Pubitemid 351599735)
61. Kato T, Monji A, Hashioka S, Kanba S (2007). Risperidone significantly inhibits interferon-gamma-induced microglial activation in vitro. Schizophrenia Research 92, 108-115. (Pubitemid 46561234)
62. Kemp DE, Ismail-Beigi F, Calabrese JR (2009). Antidepressant response associated with pioglitazone: support for an overlapping pathophysiology between major depression and metabolic syndrome. American Journal of Psychiatry 166, 619.
63. Kim HW, Rapoport SI, Rao JS (2009). Altered arachidonic acid cascade enzymes in postmortem brain from bipolar disorder patients. Molecular Psychiatry. Published online : 29 December 2009. doi: 10.1038/mp.2009.137.
64. Kim JJ, Yoon KS (1998). Stress : metaplastic effects in the hippocampus. Trends in Neuroscience 21, 505-619.
65. Kodama M, Fujioka T, Duman RS (2004). Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biological Psychiatry 56, 570-580. (Pubitemid 39336404)
66. Kohno T, Shiga T, Toyomaki A, Kusumi I, et al. (2007). Effects of lithium on brain glucose metabolism in healthy men. Journal of Clinical Psychopharmacology 27, 698-702. (Pubitemid 351339459)
67. Konradi C, Heckers S (2001). Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia. Biological Psychiatry 50, 729-742. (Pubitemid 33086760)
68. Lan MJ, Yuan P, Chen G, Manji HK (2008). Neuronal peroxisome proliferator-activated receptor gamma signaling : regulation by mood-stabilizer valproate. Journal of Molecular Neuroscience 35, 225-234.
69. Le Bec PY, Fatséas M, Denis C, Lavie E, et al. (2009). Cannabis and psychosis: search of a causal link through a critical and systematic review. Encephale 35, 377-385.
70. Lee HJ, Ertley RN, Rapoport SI, Bazinet RP, et al. (2008). Chronic administration of lamotrigine downregulates COX-2 mRNA and protein in rat frontal cortex. Neurochemical Research 33, 861-866.
71. Lee HJ, Rao JS, Ertley RN, Chang L, et al. (2007). Chronic fluoxetine increases cytosolic phospholipase A activity and arachidonic acid turnover in brain phospholipids of the unanesthetized rat. Psychopharmacology (Berlin) 190, 103-115. (Pubitemid 44885349)
72. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, et al. (1995). An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). Journal of Biological Chemistry 270, 12953-12956.
73. LeMay LG, Vander AJ and Kluger MJ (1990). The effects of psychological stress on plasma interleukin 6 activity in rats. Physiology & Behavior 47, 957-961. (Pubitemid 20171700)
74. Lewis DA, Levitt P (2002). Schizophrenia as a disorder of neurodevelopment. Annual Review of Neuroscience 25, 409-432. (Pubitemid 34748023)
75. Leykin I, Mayer R, Shinitzky M (1997). Short and long-term immunosuppressive effects of clozapine and haloperidol. Immunopharmacology 37, 75-86. (Pubitemid 27339022)
76. Li H, Zhang X, Guo Y, Ju G, et al. (2007). A case-control study of genetic association of the PLA2G4A gene with schizophrenia in a Chinese population. Psychiatry Genetics 17, 205. (Pubitemid 46716215)
77. Madrigal JL, Moro MA, Lizasoain I, Lorenzo P, et al. (2001). Inducible nitric oxide synthase expression in brain cortex after acute restraint stress is regulated by nuclear factor kappaB-mediated mechanisms. Journal of Neurochemistry 76, 532-538. (Pubitemid 32097029)
78. Madrigal JL, Hurtado O, Moro MA, Lizasoain I, et al. (2002). The increase in TNF-alpha levels is implicated in NF-kappaB activation and inducible nitric oxide synthase expression in brain cortex after immobilization stress. Neuropsychopharmacology 26, 155-163. (Pubitemid 34093078)
79. Maes M (1999). Major depression and activation of the inflammatory response system. Advances in Experimental Medicine and Biology 461, 25-46.
80. Maes M, Meltzer HY, Bosmans E (1994). Immune-inflammatory markers in schizophrenia : comparison to normal controls and effects of clozapine. Acta Psychiatrica Scandinavica 89, 346-351. (Pubitemid 24157957)
81. Maida ME, Hurley SD, Daeschner JA, Moore AH, et al. (2006). Cytosolic prostaglandin E2 synthase (cPGES) expression is decreased in discrete cortical regions in psychiatric disease. Brain Research 1103, 164-172. (Pubitemid 44080118)
82. Maier SF, Nguyen KT, Deak T, Milligan ED, et al. (1999). Stress, learned helplessness, and brain interleukin-1 beta. Advances in Experimental Medicine and Biology 461, 235-249.
83. Maier SF, Watkins LR (1998). Cytokines for psychologists: implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. Psychological Review 105, 83-107. (Pubitemid 128459559)
84. Malberg JE, Eisch AJ, Nestler EJ, Duman RS (2000). Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. Journal of Neuroscience 20, 9104-9110. (Pubitemid 32042912)
85. Marchalant Y, Brothers HM, Norman GJ, Karelina K, et al. (2009). Cannabinoids attenuate the effects of aging upon neuroinflammation and neurogenesis. Neurobiology of Disease 34, 300-307.
86. Martinowich K, Manji H, Lu B (2007). New insights into BDNF function in depression and anxiety. Nature Neuroscience 10, 1089-1093. (Pubitemid 47339961)
87. Mathur A, Law MH, Hamzehloei T, Megson IL, et al. (2009). No association between the PPARc gene and schizophrenia in a British population. Prostaglandins, Leukotrienes and Essential Fatty Acids 81, 273-277.
88. McEwen BS (1998). Protective and damaging effects of stress mediators. New England Journal of Medicine 338, 171-179.
89. McIntyre RS, Soczynska JK, Woldeyohannes HO, Lewis GF, et al. (2007). Thiazolidinediones: novel treatments for cognitive deficits in mood disorders? Expert Opinion on Pharmacotherapy 8, 1615-1628. (Pubitemid 47288172)
90. McNally L, Bhagwagar Z, Hannestad J (2008). Inflammation, glutamate, and glia in depression: a literature review. CNS Spectrums 13, 501-510. (Pubitemid 351965454)
91. Meira-Lima I, Jardim D, Junqueira R, Ikenaga E, et al. (2003). Allelic association study between phospholipase A2 genes and bipolar affective disorder. Bipolar Disorder 5, 295-299. (Pubitemid 37009892)
92. Michael-Titus AT, Bains S, Jeetle J, Whelpton R (2000). Imipramine and phenelzine decrease glutamate overflow in the prefrontal cortex-a possible mechanism of neuroprotection in major depression? Neuroscience 100, 681-684.
93. Miller AH, Maletic V, Raison CL (2009). Inflammation and its discontents : the role of cytokines in the pathophysiology of major depression. Biological Psychiatry 65, 732-741.
94. Mizoguchi K, Ishige A, Takeda S, Aburada M, et al. (2004). Endogenous glucocorticoids are essential for maintaining prefrontal cortical cognitive function. Journal of Neuroscience 24, 5492-5499. (Pubitemid 38812631)
95. Mizuno M, Sotoyama H, Narita E, Kawamura H, et al. (2007). A cyclooxygenase-2 inhibitor ameliorates behavioral impairments induced by striatal administration of epidermal growth factor. Journal of Neuroscience 27, 10116-10127. (Pubitemid 47450461)
96. Moghaddam B (1993). Stress preferentially increases extraneuronal levels of excitatory amino acids in the prefrontal cortex : comparison to hippocampus and basal ganglia. Journal of Neurochemistry 60, 1650-1657. (Pubitemid 23127567)
97. Molina V, Gispert JD, Reig S, Pascau J, et al. (2005). Olanzapine-induced cerebral metabolic changes related to symptom improvement in schizophrenia. International Clinical Psychopharmacology 20, 13-18. (Pubitemid 40105543)
98. Moncada S, Palmer RM, Higgs EA (1991). Nitric oxide : physiology, pathophysiology, and pharmacology. Pharmacological Reviews 43, 109-142.
99. Monji A, Kato T, Kanba S (2009). Cytokines and schizophrenia : microglia hypothesis of schizophrenia. Psychiatry and Clinical Neurosciences 63, 257-265.
100. Mü ller N, Empl M, Riedel M, Schwarz M, et al 1997 Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience 247 308-313.
101. Mü ller N, Riedel M, Scheppach C, Brandstätter B, et al. (2002). Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. American Journal of Psychiatry 159, 1029-1034.
102. Mü ller N, Schwarz MJ 2008). A psychoneuroimmunological perspective to Emil Kraepelins dichotomy: schizophrenia and major depression as inflammatory CNS disorders. European Archives of Psychiatry and Clinical Neuroscience 258 (Suppl. 2) 97-106.
103. Mü ller N, Schwarz MJ, Dehning S, Douhe A, et al 2006 The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Molecular Psychiatry 11 680-684.
104. Murakami M, Nakatani Y, Tanioka T, Kudo I (2002). Prostaglandin E synthase. Prostaglandins & Other Lipid Mediators 68-69, 383-399. (Pubitemid 35247409)
105. Myers CS, Contreras MA, Chang MC, Rapoport SI, et al. (2001). Haloperidol downregulates phospholipase A(2) signaling in rat basal ganglia circuits. Brain Research 896, 96-101. (Pubitemid 32244152)
106. Myint AM, Steinbusch HW, Goeghegan L, Luchtman D, et al. (2007). Effect of the COX-2 inhibitor celecoxib on behavioural and immune changes in an olfactory bulbectomised rat model of depression. Neuroimmunomodulation 14, 65-71. (Pubitemid 47442983)
107. Nadalin S, Rubesa G, Giacometti J, Vulin M, et al. (2008). BanI polymorphism of cytosolic phospholipase A2 gene is associated with age at onset in male patients with schizophrenia and schizoaffective disorder. Prostaglandins, Leukotrienes and Essential Fatty Acids 78, 351-360.
108. Nair A, Bonneau RH (2006). Stress-induced elevation of glucocorticoids increases microglia proliferation through NMDA receptor activation. Journal of Neuroimmunology 171, 72-85. (Pubitemid 41832279)
109. Nemets B, Stahl Z, Belmaker RH (2002). Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. American Journal of Psychiatry 159, 477-479. (Pubitemid 34184747)
110. Nery FG, Monkul ES, Hatch JP, Fonseca M, et al. (2008). Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder : a double-blind, randomized, placebo-controlled study. Human Psychopharmacology 23, 87-94. (Pubitemid 351359580)
111. Nibuya M, Morinobu S, Duman RS (1995). Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. Journal of Neuroscience 15, 7539-7547.
112. Norrholm SD, Ouimet CC (2001). Altered dendritic spine density in animal models of depression and in response to antidepressant treatment. Synapse 42, 151-163. (Pubitemid 32999622)
113. O'Sullivan SE (2007). Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. British Journal of Pharmacology 152, 576-582.
114. Pace TW, Hu F, Miller AH (2007). Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain Behavior & Immunity 21, 9-19. (Pubitemid 44872932)
115. Pae CU, Yu HS, Kim JJ, Lee CU, et al. (2004a). BanI polymorphism of the cytosolic phospholipase A2 gene and mood disorders in the Korean population. Neuropsychobiology 49, 185-188.
116. Pae CU, Yu HS, Lee KU, Kim JJ, et al. (2004b). BanI polymorphism of the cytosolic phospholipase A2 gene may confer susceptibility to the development of schizophrenia. Progress in Neuropsychopharmacology and Biological Psychiatry 28, 739-741.
117. Pandey GN, Dwivedi Y, SridharaRao J, Ren X, et al. (2002). Protein kinase C and phospholipase C activity and expression of their specific isozymes is decreased and expression of MARCKS is increased in platelets of bipolar but not in unipolar patients. Neuropsychopharmacology 26, 216-228. (Pubitemid 34093084)
118. Park EY, Cho IJ, Kim SG (2004). Transactivation of the PPAR-responsive enhancer module in chemopreventive glutathione S-transferase gene by the peroxisome proliferator-activated receptor-gamma and retinoid X receptor heterodimer. Cancer Research 64, 3701-3713. (Pubitemid 38657951)
119. Pavlov VA, Tracey KJ (2005). The cholinergic antiinflammatory pathway. Brain Behavior & Immunity 19, 493-499.
120. Pecchi E, Dallaporta M, Jean A, Thirion S, et al. (2009). Prostaglandins and sickness behavior: old story, new insights. Physiological Behavior 97, 279-292.
121. Peet M, Horrobin DF (2002). A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Archives of General Psychiatry 59, 913-919.
122. Pereira MP, Hurtado O, Cárdenas A, Alonso-Escolano D, et al. (2006). The nonthiazolidinedione PPARgamma agonist L-796,449 is neuroprotective in experimental stroke. Journal of Neuropathology and Experimental Neurology 64, 797-805.
123. Phillis JW, Horrocks LA and Farooqui AA (2006). Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: their role and involvement in neurological disorders. Brain Research Reviews 52, 201-243. (Pubitemid 44291802)
124. Potvin S, Stip E, Sepehry AA, Gendron A, et al. (2008). Inflammatory cytokine alterations in schizophrenia : a systematic quantitative review. Biological Psychiatry 63, 801-808. (Pubitemid 351410515)
125. Price G, CercignaniM, Parker GJ, Altmann DR, et al. (2007). Abnormal brain connectivity in first-episode psychosis: a diffusion MRI tractography study of the corpus callosum. Neuroimage 35, 458-466. (Pubitemid 46400557)
126. Puri BK, Counsell SJ, Hamilton G, Richardson AJ, et al. (2001). Eicosapentaenoic acid in treatment-resistant depression associated with symptom remission, structural brain changes and reduced neuronal phospholipid turnover. International Journal of Clinical Practice 55, 560-563. (Pubitemid 33040558)
127. Qu Y, Chang L, Klaff J, Seemann R, et al. (2006). Chronic fluoxetine upregulates arachidonic acid incorporation into the brain of unanesthetized rats. European Neuropsychopharmacology 16, 561-571. (Pubitemid 44716660)
128. Raison CL, Miller AH (2003). When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. American Journal of Psychiatry 160, 1554-1565. (Pubitemid 41079539)
129. Raison CL, Capuron L, Miller AH (2006). Cytokines sing the blues : inflammation and the pathogenesis of depression. Trends in Immunology 27, 24-31. (Pubitemid 43083561)
130. Rantamäki T, Hendolin P, Kankaanpää A, Mijatovic J, et al. (2007). Pharmacologically diverse antidepressants rapidly activate brain-derived neurotrophic factor receptor TrkB and induce phospholipase-Cgamma signaling pathways in mouse brain. Neuropsychopharmacology 32, 2152-2162. (Pubitemid 47417694)
131. Rao JS, Ertley RN, Lee HJ, Rapoport SI, et al. (2006). Chronic fluoxetine upregulates activity, protein and mRNA levels of cytosolic phospholipase A2 in rat frontal cortex. Pharmacogenomics Journal 6, 413-420. (Pubitemid 44811537)
132. Rao JS, Bazinet RP, Rapoport SI, Lee HJ (2007a). Chronic treatment of rats with sodium valproate downregulates frontal cortex NF-kappaB DNA binding activity and COX-2 mRNA. Bipolar Disorder 9, 513-520. (Pubitemid 47202514)
133. Rao JS, Ertley RN, Rapoport SI, Bazinet RP, Lee HJ, et al. (2007b). Chronic NMDA administration to rats up-regulates frontal cortex cytosolic phospholipase A2 and its transcription factor, activator protein-2. Journal of Neurochemistry 102, 1918-1927. (Pubitemid 47329252)
134. Rasgon NL, Kenna HA, Williams KE, Powers B, et al. (2010). Rosiglitazone add-on in treatment of depressed patients with insulin resistance : a pilot study. Scientific World Journal 10, 321-328.
135. Reif A, Herterich S, Strobel A, Ehlis AC, et al. (2006). A neuronal nitric oxide synthase (NOS-I) haplotype associated with schizophrenia modifies prefrontal cortex function. Molecular Psychiatry 11, 286-300.
136. Rollins B, Martin MV, Sequeira PA, Moon EA, et al. (2009). Mitochondrial variants in schizophrenia, bipolar disorder, and major depressive disorder. PLoS One 4, e4913.
137. Rosa AO, Kaster MP, Binfaré RW, Morales S, et al. (2008). Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice. Progress in Neuropsychopharmacology and Biological Psychiatry 32, 1549-1556.
138. Ross BM, Hudson C, Erlich J, Warsh JJ, et al. (1997). Increased phospholipid breakdown in schizophrenia. Evidence for the involvement of a calcium-independent phospholipase A2. Archives of General Psychiatry 54, 487-494. (Pubitemid 27198211)
139. Ross BM, Turenne S, Moszczynska A, Warsh JJ, et al. (1999). Differential alteration of phospholipase A2 activities in brain of patients with schizophrenia. Brain Research 821, 407-413. (Pubitemid 29222805)
140. Schiltz JC, Sawchenko PE (2003). Signaling the brain in systemic inflammation: the role of perivascular cells. Frontiers in Bioscience 8, s1321-s1329. (Pubitemid 38925390)
141. Seibert K, Masferrer J, Zhang Y, Leahy K, et al. (1995). Expression and selective inhibition of constitutive and inducible forms of cyclooxygenase. Advances in Prostaglandin, Thromboxane and Leukotriene Research 23, 125-127.
142. Shao L, Young LT, Wang JF (2005). Chronic treatment with mood stabilizers lithium and valproate prevents excitotoxicity by inhibiting oxidative stress in rat cerebral cortical cells. Biological Psychiatry 58, 879-884. (Pubitemid 41790716)
143. Sinor JD, Du S, Venneti S, Blitzblau RC, et al. (2000). NMDA and glutamate evoke excitotoxicity at distinct cellular locations in rat cortical neurons in vitro. Journal of Neuroscience 20, 8831-8837.
144. Smesny S, Kinder D, Willhardt I, Rosburg T, et al. (2005). Increased calcium-independent phospholipase A2 activity in first but not in multiepisode chronic schizophrenia. Biological Psychiatry 57, 399-405. (Pubitemid 40215770)
145. Smith GS, Kramer E, Hermann C, Ma Y, Dhawan V, et al. (2009). Serotonin modulation of cerebral glucose metabolism in depressed older adults. Biological Psychiatry 66, 259-266.
146. Song C, Lin A, Kenis G, Bosmans E, et al. (2000). Immunosuppressive effects of clozapine and haloperidol: enhanced production of the interleukin-1 receptor antagonist. Schizophrenia Research 42, 157-164. (Pubitemid 30163081)
147. Song C, Zhang XY, Manku M (2009a). Increased phospholipase A2 activity and inflammatory response but decreased nerve growth factor expression in the olfactory bulbectomized rat model of depression: effects of chronic ethyl-eicosapentaenoate treatment. Journal of Neuroscience 29, 14-22.
148. Song XQ, Lv LX, Li WQ, Hao YH, et al. (2009b). The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia. Biological Psychiatry 65, 481-488.
149. Sorrells SF, Caso JR, Munhoz CD, Sapolsky RM (2009). The stressed CNS: when glucocorticoids aggravate inflammation. Neuron 15, 33-39.
150. Sorrells SF, Sapolsky RM (2007). An inflammatory review of glucocorticoid actions in the CNS. Brain Behaviour & Immunity 21, 259-272. (Pubitemid 46199119)
151. Steiner J, Bielau H, Brisch R, Danos P, et al. (2008). Immunological aspects in the neurobiology of suicide : elevated microglial density in schizophrenia and depression is associated with suicide. Journal of Psychiatric Research 42, 151-157. (Pubitemid 350061255)
152. Stone JM,Morrison PD, Pilowsky LS (2007). Glutamate and dopamine dysregulation in schizophrenia - a synthesis and selective review. Journal of Psychopharmacology 21, 440-452. (Pubitemid 47077295)
153. Stolk P, Souverein PC, Leufkens HG, Weil JG, et al. (2007). The association between exposure to COX-2 inhibitors and schizophrenia deterioration. A nested case-control study. Pharmacopsychiatry 40, 111-115. (Pubitemid 46910382)
154. Sugino H, Futamura T, Mitsumoto Y, Maeda K, et al. (2009). Atypical antipsychotics suppress production of proinflammatory cytokines and up-regulate interleukin-10 in lipopolysaccharide-treated mice. Progress in Neuropsychopharmacology and Biological Psychiatry 33, 303-307.
155. Sun SL, Liu Y, Wei J, Liu SZ, et al. (2008). The PPAR-d gene may be associated with schizophrenia in a Chinese population. Psychiatry Genetics 18, 253-254.
156. Sun Y, Bennett A (2007). Cannabinoids : a new group of agonists of PPARs. PPAR Research 2007, 23513.
157. Tao R, Yu Y, Zhang X, Guo Y, et al. (2005a). Cytosolic PLA2 genes possibly contribute to the etiology of schizophrenia. American Journal of Medical Genetics 137B, 56-58. (Pubitemid 41076615)
158. Tao R, Yu Y, Zhang X, Shi J, et al. (2005b). A family based study of the genetic association between the PLA2G4D gene and schizophrenia. Prostaglandins, Leukotrienes and Essential Fatty Acids 73, 419-422. (Pubitemid 41563005)
159. Toyomoto M, Ohta M, Okumura K, Yano H, et al. (2004). Prostaglandins are powerful inducers of NGF and BDNF production in mouse astrocyte cultures. FEBS Letters 562, 211-215. (Pubitemid 38388474)
160. Tracey KJ, Czura CJ, Ivanova S (2001). Mind over immunity. FASEB Journal 15, 1575-1576. (Pubitemid 32673388)
161. Urade Y, Hayaishi O (2000). Biochemical, structural, genetic, physiological, and pathophysiological features of lipocalin-type prostaglandin D synthase. Biochimica and Biophysica Acta 1482, 259-271.
162. Van Berckel BN, Bossong MG, Boellaard R, Kloet R, et al. (2008). Microglia activation in recent-onset schizophrenia : a quantitative (R)-[11C]PK11195 positron emission tomography study. Biological Psychiatry 64, 820-822.
163. Van der Stelt M, Veldhuis WB, Maccarrone M, Bär PR, et al. (2002). Acute neuronal injury, excitotoxicity, and the endocannabinoid system. Molecular Neurobiology 26, 317-346. (Pubitemid 35239807)
164. Walker E, Mittal V, Tessner K (2008). Stress and the hypothalamic pituitary adrenal axis in the developmental course of schizophrenia. Annual Review of Clinical Psychology 4, 189-216. (Pubitemid 351668616)
165. Wei J, Hemmings GP (2004). A study of a genetic association between the PTGS2/PLA2G4A locus and schizophrenia. Prostaglandins, Leukotrienes and Essential Fatty Acids 70, 413-415. (Pubitemid 38429277)
166. Wexler EM, Geschwind DH, Palmer TD (2008). Lithium regulates adult hippocampal progenitor development through canonical Wnt pathway activation. Molecular Psychiatry 13, 285-292. (Pubitemid 351272655)
167. Wolkowitz OM, Epel ES, Reus VI (2001). Stress hormonerelated psychopathology: pathophysiological and treatment implications. World Journal of Biological Psychiatry 2, 115-143.
168. Yasuda S, Liang MH, Marinova Z, Yahyavi A, Chuang DM (2009). The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Molecular Psychiatry 14, 51-59.
169. Yao JK, Leonard S, Reddy RD (2004). Increased nitric oxide radicals in postmortem brain from patients with schizophrenia. Schizophrenia Bulletin 30, 923-934. (Pubitemid 40469526)
170. Yokota O, Terada S, Ishihara T, Nakashima H, et al. (2004). Neuronal expression of cyclooxygenase-2, a proinflammatory protein, in the hippocampus of patients with schizophrenia. Progress in Neuropsychopharmacology and Biological Psychiatry 28, 715-721. (Pubitemid 38987397)
171. Yu Y, Tao R, Shi J, Zhang X, et al. (2005). A genetic study of two calcium-independent cytosolic PLA2 genes in schizophrenia. Prostaglandins, Leukotreienes and Essential Fatty Acids 73, 351-354. (Pubitemid 41375630)
172. Yu YQ, Tao R, Wei J, Xu Q, et al. (2004). No association between the PTGS2/PLA2G4A locus and schizophrenia in a Chinese population. Prostaglandins, Leukotrienes and Essential Fatty Acids 71, 405-408. (Pubitemid 39425083)
173. Zandi PP, Belmonte PL, Willour VL, Goes FS, et al. (2008). Association study of Wnt signaling pathway genes in bipolar disorder. Archives of General Psychiatry 65, 785-793. (Pubitemid 351957704)
174. Zhang Z, Zhang ZY, Fauser U, Schluesener HJ (2008). Valproic acid attenuates inflammation in experimental autoimmune neuritis. Cellular & Molecular Life Sciences 65, 4055-4065.
175. Zhou M, Wu R, Dong W, Jacob A, et al. (2008). Endotoxin downregulates peroxisome proliferator-activated receptor-gamma via the increase in TNF-alpha release. AJP - Regulatory, Integrative and Comparative Physiology 294, R84-R92.